Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 6/20 | 1.00 |
| ▸ | NPC1L1 | Q9UHC9 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 4/20 | 1.00 |
| ▸ | RORA | P35398 | 3/20 | 1.00 |
| ▸ | OSBP | P22059 | 4/20 | 0.80 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083017 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL2530829 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL289219 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL6392982 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL281942 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL23810015 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL21617323 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL22959572 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL22959500 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP | |
| SCHEMBL6389457 | 1.00 | GPR183 (1.00) | GPR183NPC1L1RORCRORAOSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120000614-A | Composite lipid nanoparticle containing cryoprotectant and preparation method and application thereof | 中国科学院化学研究所 | 2025-05-16 | — | — | CN | claimed |
| CN-119912352-A | Fluoro lipid nano-particles and preparation method and application thereof | 中国科学院化学研究所 | 2025-05-02 | — | — | CN | claimed |
| CN-118338907-A | Lipid Nanoparticle (LNP) compositions and methods of using the same | 宾夕法尼亚大学董事会 | 2024-07-12 | — | — | CN | claimed |
| US-12029822-B2 | Drug delivery systems containing oxidized cholesterols | GEORGIA TECH RESEARCH CORPORATION (US) | 2024-07-09 | — | — | US | claimed |
| WO-2024109612-A1 | METHOD FOR PREPARING LIPID NANOPARTICLE FOR EFFICIENTLY DELIVERING NUCLEIC ACID DRUG AND USE THEREOF | 中国科学院化学研究所 | 2024-05-30 | — | — | WO | claimed |
| CN-118059061-A | Preparation method and application of lipid nanoparticle for efficiently delivering nucleic acid drug | 中国科学院化学研究所 | 2024-05-24 | — | — | CN | claimed |
| CN-118045169-A | Lipid-charged molecule conjugate, inhalable lipid nanoparticle, and preparation method and application thereof | 中国科学院化学研究所 | 2024-05-17 | — | — | CN | claimed |
| WO-2024078193-A1 | LIPID NANOPARTICLE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院化学研究所 | 2024-04-18 | — | — | WO | claimed |
| CN-116763756-A | Lipid nanoparticle and preparation method and application thereof | 中国科学院化学研究所 | 2023-09-19 | — | — | CN | claimed |
| CN-116549461-A | Compositions comprising 7β -hydroxycholesterol and lipid vehicle and their use in the treatment of oncological conditions | 倍塔因诺弗公司 | 2023-08-08 | — | — | CN | claimed |
| US-20140221236-A1 | METABOLOMIC MARKERS FOR PRETERM BIRTH | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2014-08-07 | — | — | US | claimed |
| EP-2522350-B1 | Use of the active ingredient combination of a 1-diethylaminoethyl-3-chinoxalin-2-on derivative and an oxysterol for breaking resistance in the treatment of cancer and strengthening the immune system against cancer, bacterial and viral diseases, autoimmune diseases, increased stress and environmental influences | IMMUNOPHARM AG (LI) | 2013-07-31 | — | — | EP | claimed |
| EP-1742636-B1 | Preparation for the treatment cancer | IMMUNOPHARM AG (LI) | 2013-04-10 | — | — | EP | claimed |
| EP-1827379-B1 | FORMULATIONS CONTAINING ALKYLPHOSPHOCHOLINES USING NOVEL NEGATIVE CHARGE CARRIERS | MAX PLANCK GESELLSCHAFT (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20080200424-A1 | Preparation for Treating Cancer | IMMUNOPHARM AG (LI) | 2008-08-21 | — | — | US | claimed |
| US-20080090781-A1 | Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1287016-B1 | RADIOIMAGING PROBES AND THE USE THEREOF | GENESIS GROUP INC (CA) | 2004-09-15 | — | — | EP | claimed |
| US-20030194372-A1 | Radioimaging probes and the use thereof | LIU HU (CA) | 2003-10-16 | — | — | US | claimed |
| US-6423702-B1 | PROCESS FOR THE HYDROXYLATION OF AN ACYCLIC OR CYCLIC METHYLENE RADICAL IN THE ALLYLIC POSITION, PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYCHOLESTEROL DERIVATIVES AND UTILIZATION OF SUCH COMPOSITIONS FOR THE PREPARATION OF DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-07-23 | — | — | US | claimed |
| EP-0540649-B1 | PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYCHOLESTEROL DERIVATIVES AND UTILISATION OF SUCH COMPOSITIONS FOR THE PREPARATION OF DRUGS | CENTRE NAT RECH SCIENT (FR) | 1998-12-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090781-A1 | Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers | PHOSPHO1, SGMS2, LPCAT1 | GPR183 734/4885NPC1L1 52/4885RORC 3000/4885 |
| US-20030194372-A1 | Radioimaging probes and the use thereof | LDLR, ASGR1, LIPG | GPR183 55/4885NPC1L1 17/4885RORC 1872/4885 |
| US-20080200424-A1 | Preparation for Treating Cancer | CBS, SCLY, GPX1 | GPR183 1832/4885NPC1L1 210/4885RORC 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.